Clinical Trial Update: REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial REVEAL exploring NKTR-262 with NKTR-214 and nivolumab in various locally advanced/metastatic solid tumors was terminated; results posted in 2023…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Merkel Cell Carcinoma
• Renal Cell Carcinoma
• Sarcoma
• Triple-negative Breast Cancer

Drugs mentioned

• NKTR-214 (bempegaldesleukin)
• NKTR-262
• nivolumab (nivolumab)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Melanoma, Merkel Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-03-08